Jason Duncan insider trades: Albireo Pharma (ALBO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | ALBO | ↓ Sell10b5-1 | 228 | $43.80 | $10K | Direct | Jan 23, 2023 (0d) |
| Jan 19, 2023 | ALBO | ↓ Sell10b5-1 | 938 | $43.90 | $41K | Direct | Jan 20, 2023 (1d) |
| Oct 24, 2022 | ALBO | ↓ Sell10b5-1 | 656 | $19.45 | $13K | Direct | Oct 25, 2022 (1d) |
| Jul 25, 2022 | ALBO | ↓ Sell10b5-1 | 657 | $24.21 | $16K | Direct | Jul 25, 2022 (0d) |
| Apr 25, 2022 | ALBO | ↓ Sell10b5-1 | 655 | $33.22 | $22K | Direct | Apr 25, 2022 (0d) |
| Jan 24, 2022 | ALBO | ↓ Sell10b5-1 | 1,688 | $24.94 | $42K | Direct | Jan 25, 2022 (1d) |
| Oct 25, 2021 | ALBO | ↓ Sell10b5-1 | 312 | $29.10 | $9K | Direct | Oct 25, 2021 (0d) |
| Jul 23, 2021 | ALBO | ↓ Sell10b5-1 | 313 | $32.21 | $10K | Direct | Jul 26, 2021 (3d) |
| Jun 25, 2021 | ALBO | ↓ Sell | 16,300 | $36.32 | $592K | Direct | Jun 28, 2021 (3d) |
| Apr 23, 2021 | ALBO | ↓ Sell10b5-1 | 312 | $32.16 | $10K | Direct | Apr 26, 2021 (3d) |
| Apr 1, 2021 | ALBO | ↓ Sell | 1,726 | $35.24 | $61K | Direct | Apr 2, 2021 (1d) |
| Jan 22, 2021 | ALBO | ↓ Sell | 110 | $34.62 | $4K | Direct | Jan 25, 2021 (3d) |
| Oct 22, 2020 | ALBO | ↓ Sell | 89 | $34.71 | $3K | Direct | Oct 23, 2020 (1d) |
| Sep 8, 2020 | ALBO | ↓ Sell | 4,000 | $45.55 | $182K | Direct | Sep 10, 2020 (2d) |
| Jul 22, 2020 | ALBO | ↓ Sell | 91 | $25.80 | $2K | Direct | Jul 23, 2020 (1d) |
| Apr 22, 2020 | ALBO | ↓ Sell | 92 | $17.68 | $2K | Direct | Apr 24, 2020 (2d) |
| Jan 22, 2020 | ALBO | ↓ Sell | 447 | $23.97 | $11K | Direct | Jan 23, 2020 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jason Duncan's insider trades
Jason Duncan is Chief Legal Officer and GC at Albireo Pharma (ALBO). Since Jan 22, 2020, Jason has reported no open-market purchases and 17 sales worth $1.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
9 sales (17% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (10 filings), shares returned to the company (3 filings), option exercises (3 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALBO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.